Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus (ESSTIM)
Primary Purpose
Systemic Lupus Erythematosus
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
therapeutic education
Sponsored by
About this trial
This is an interventional prevention trial for Systemic Lupus Erythematosus focused on measuring systemic lupus erythematosus, antimalarials, therapeutic education, Coping questionnaire, MASRI questionnaire, morisky medication adherence scale, lupus Quality Of Life, internal medicine
Eligibility Criteria
Inclusion Criteria:
- patients with a systemic lupus with ACR criteria (at least 4 criterias)
- patients with antimalarials for at least 3 months with a minimum dose of 200 mg/day.
Exclusion Criteria:
- patients who refuse to sign the informed consent
- patients who are under guardianship
Sites / Locations
- CH Hôpital Duchenne
- CH Douai
- CH Dunkerque
- CH du Dr Schaffner
- CHRU, Hôpital Huriez
- Victor Provo Hospital
- Valenciennes hospital
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Patients with Systemic Lupus
Arm Description
Outcomes
Primary Outcome Measures
measure of the frequency of patients with systemic lupus noncompliants to their antimalarials treatment.
Secondary Outcome Measures
hydroxychloroquinémie
Monitoring of blood levels of hydroxychloroquinémie
number of non- adherent patients
Identification of the number of non- adherent patients are being enrolled in Education Protocol Patient and number of sessions followed ;
quality of life scale Coping
scale Coping ( WCC-R Par COUSSON et al. (1996) ) scale MASRI, scale MMAS-8-item
Full Information
NCT ID
NCT02364908
First Posted
February 10, 2015
Last Updated
October 12, 2018
Sponsor
University Hospital, Lille
Collaborators
Région Nord-Pas de Calais, France
1. Study Identification
Unique Protocol Identification Number
NCT02364908
Brief Title
Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
Acronym
ESSTIM
Official Title
Prospective Evaluation of Adherence to Antimalarials in Patients With Systemic Lupus and Role of Therapeutic Education
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
December 2014 (Actual)
Primary Completion Date
November 30, 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
Collaborators
Région Nord-Pas de Calais, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a biomedical, open label, therapeutic strategy, interventional, non-randomized, multicenter study to evaluate the non compliance to antimalarials in patients with systemic lupus in the Nord Pas-de-Calais region (FRANCE). It is conducted in two visits. These visits consist in obtaining blood sample, performing a clinical examination and filling in a questionnaire (Quality Of Life, Coping...).
The goal for the noncompliants patients is to guide them towards the therapeutic education with professionals (nurses and physicians).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Lupus Erythematosus
Keywords
systemic lupus erythematosus, antimalarials, therapeutic education, Coping questionnaire, MASRI questionnaire, morisky medication adherence scale, lupus Quality Of Life, internal medicine
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
158 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Patients with Systemic Lupus
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
therapeutic education
Intervention Description
This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
Primary Outcome Measure Information:
Title
measure of the frequency of patients with systemic lupus noncompliants to their antimalarials treatment.
Time Frame
baseline, at 12 months
Secondary Outcome Measure Information:
Title
hydroxychloroquinémie
Description
Monitoring of blood levels of hydroxychloroquinémie
Time Frame
between 6 months at 12 months
Title
number of non- adherent patients
Description
Identification of the number of non- adherent patients are being enrolled in Education Protocol Patient and number of sessions followed ;
Time Frame
at 12 months
Title
quality of life scale Coping
Description
scale Coping ( WCC-R Par COUSSON et al. (1996) ) scale MASRI, scale MMAS-8-item
Time Frame
baseline, at 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with a systemic lupus with ACR criteria (at least 4 criterias)
patients with antimalarials for at least 3 months with a minimum dose of 200 mg/day.
Exclusion Criteria:
patients who refuse to sign the informed consent
patients who are under guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Hachulla, MD, PhD
Organizational Affiliation
University Hospital, Lille
Official's Role
Study Chair
Facility Information:
Facility Name
CH Hôpital Duchenne
City
Boulogne sur Mer
ZIP/Postal Code
62321
Country
France
Facility Name
CH Douai
City
Douai
ZIP/Postal Code
59507
Country
France
Facility Name
CH Dunkerque
City
Dunkerque
ZIP/Postal Code
59385
Country
France
Facility Name
CH du Dr Schaffner
City
Lens
ZIP/Postal Code
62307
Country
France
Facility Name
CHRU, Hôpital Huriez
City
Lille
Country
France
Facility Name
Victor Provo Hospital
City
Roubaix
ZIP/Postal Code
59056
Country
France
Facility Name
Valenciennes hospital
City
Valenciennes
ZIP/Postal Code
59322
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
We'll reach out to this number within 24 hrs